ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.

April 12, 2007 10:41 ET

ALDA Targets Large Market for Treatment of Genital Infections

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 12, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has established that the global market for treating VulvoVaginal Infections ("VVI's") is approximately $2 Billion annually. Yeast infections are probably the most well-known form of VVI, but actually cause less than one third of these infections. The remaining two thirds of VVI's are caused by bacteria, and combinations of infectious organisms. Treatments for yeast infections are not effective against these other types of VVI's or against yeast species that have developed antibiotic resistance. Current treatments for VVI's that are not caused by yeasts also have serious limitations. The lack of effective treatments for the large majority of VVI's has created an opportunity for ALDA because ALDA's T36® technology is known to kill all types of infectious organisms. This broad capability will allow ALDA to pursue the entire VVI market rather than just the limited portion represented by yeast infections.

About ALDA

ALDA's patent-pending T36® formulation contains active ingredients in very low concentrations that act in concert to disrupt the physical structure of all infectious organisms rather than interfering with their metabolic pathways. The competitive advantage of this approach is the ability to kill all infectious organisms while preventing microbial resistance, side effects or toxicity.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information